KCNH2 and Prolonged QT interval: Although there is specific pharmacology against hERG1, its usage to treat hERG1 in leukemias is handicapped by the fact that cardiac hERG1 may be also affected, producing long QT-syndrome, which can eventually cause a fatal fibrillation.